Search results
Results from the WOW.Com Content Network
Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication following its continuous use of at least a month. [5]
Some side effects, such as weight gain, occur more frequently with certain types of antidepressant medication. Switching to a new type of antidepressant may help reverse any weight gain you’ve ...
Serious side effects may include liver problems, angioedema, kidney problems, and high blood potassium. [1] Use in pregnancy and breastfeeding is not recommended. [5] It is an ACE inhibitor and works by decreasing renin-angiotensin-aldosterone system activity. [1] Ramipril was patented in 1981 and approved for medical use in 1989. [6]
The rebound effect, or pharmaceutical rebound phenomenon, is the emergence or re-emergence of symptoms that were either absent or controlled while taking a medication, but appear when that same medication is discontinued, or reduced in dosage. In the case of re-emergence, the severity of the symptoms is often worse than pretreatment levels.
People who had moderate or severe digestive side effects were more likely to stop the medications. In severe cases, patients have sued drugmakers contending the medications led to lasting harms.
addictive drug – psychoactive substances that with repeated use are associated with significantly higher rates of substance use disorders, due in large part to the drug's effect on brain reward systems; dependence – an adaptive state associated with a withdrawal syndrome upon cessation of repeated exposure to a stimulus (e.g., drug intake)
“In the brain, GLP-1 receptors act like a stop light and tell certain areas of the brain to stop releasing dopamine, the feel-good chemical that reinforces compulsive or addictive behavior, like ...
Some believe ramipril's additional benefits may be shared by some or all drugs in the ACE-inhibitor class. However, ramipril currently remains the only ACE inhibitor for which such effects are actually evidence-based. [68] A meta-analysis confirmed that ACE inhibitors are effective and certainly the first-line choice in hypertension treatment.